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Background/Aim: Hepatic stellate cells (HSCs) express a-smooth muscle actin (aSMA) and acquire a
profibrogenic phenotype upon activation by noxious stimuli. Insulin-like growth I (IGF-I) has been shown to
stimulate HSCs proliferation in vitro, but it has been reported to reduce liver damage and fibrogenesis
when given to cirrhotic rats.
Methods: The authors used transgenic mice (SMP8-IGF-I) expressing IGF-I under control of aSMA
promoter to study the influence of IGF-I synthesised by activated HSCs on the recovery from liver injury.
Results: The transgene was expressed by HSCs from SMP8-IGF-I mice upon activation in culture and in the
livers of these animals after CCl4 challenge. Twenty four hours after administration of CCl4 both transgenic
and wild type mice showed similar extensive necrosis and increased levels of serum transaminases.
However at 72 hours SMP8-IGF-I mice exhibited lower serum transaminases, reduced hepatic expression
of aSMA, and improved liver morphology compared with wild type littermates. Remarkably, at this time all
eight CCl4 treated wild type mice manifested histological signs of liver necrosis that was severe in six of
them, while six out of eight transgenic animals had virtually no necrosis. In SMP8-IGF-I mice robust DNA
synthesis occurred earlier than in wild type animals and this was associated with enhanced production of
HGF and lower TGFb1 mRNA expression in the SMP8-IGF-I group. Moreover, Cola1(I) mRNA abundance
at 72 hours was reduced in SMP8-IGF-I mice compared with wild type controls.
Conclusions: Targeted overexpression of IGF-I by activated HSCs restricts their activation, attenuates
fibrogenesis, and accelarates liver regeneration. These effects appear to be mediated in part by
upregulation of HGF and downregulation of TGFb1. The data indicate that IGF-I can modulate the
cytokine response to liver injury facilitating regeneration and reducing fibrosis.
A
ctivation of hepatic stellate cells (HSCs), the main
producers of liver collagen, involves induction of
smooth muscle alpha actin (aSMA) and conversion
from quiescent to proliferative, collagen expressing pheno-
type.1 A number of recent studies have focused attention on
role of insulin-like growth factor I (IGF-I) in liver disease and
HSC biology. In normal liver, IGF-I is synthesised at high
levels in hepatocytes and in multiple non-parenchymal cell
types2 including HSCs.3 4 Normal hepatocytes express 5–20
fold higher levels of IGF-I than non-parenchymal cells,2 and
hepatocyte derived IGF-I is the major source of circulating
IGF-I.5 Circulating IGF-I mediates growth of multiple tissues
but appears to have little effect on growth of normal liver
because normal hepatocytes express few IGF-I receptors.2 6
During chronic liver disease, serum IGF-I levels are decreased
and provide a useful index of hepatocellular dysfunction and
impaired nutritional status.1 3 Prior studies in a rat model of
chronic, CCl4 induced liver cirrhosis indicate that systemic
administration of IGF-I improves nutritional status and liver
function7 and reduces oxidative damage and fibrosis.8
Hepatic stellate cells are known targets for IGF-I action. In
cultured HSCs, IGF-I increases proliferation3 4 9–14 and col-
lagen synthesis,8 providing indirect evidence that IGF-I could
play a role in expansion of activated HSCs and in liver
fibrosis. Quiescent HSCs, however, are continuously exposed
to high local concentrations of IGF-I in normal liver and, yet,
do not proliferate despite expression of high levels of type 1
IGF receptor (IGFIR).4 15 In addition, IGF-I stimulates
production of hepatocyte growth factor (HGF) in hepatic
stellate cells.16 17 HGF is not only a potent mitogen for
hepatocytes18 but also appears to limit liver fibrosis in vivo.19
This suggests that IGF-I could indirectly act on HSC to
stimulate the production of HGF which in turn could protect
hepatocytes from injury or promote hepatocellular regenera-
tion. Hence, the biological role of IGF-1 in the damaged liver
has not yet been well defined and present concepts are
mainly based on in vitro evidence.
It has been shown that HSCs can affect the rate of
hepatocyte regeneration by regulating extracellular matrix
(ECM) composition.1 Also, transforming growth factor beta 1
(TGFb1), a major stimulus of ECM production in HSCs,1 has
an inhibitory effect on replication of hepatocytes.20 Recent
studies have demonstrated that interruption of TGFb1
signalling improves liver fibrosis21 22 and stimulates liver
regeneration,22 indicating that TGFb1 strongly influences the
biology of both HSCs and hepatocytes.
In this study we used transgenic mice (SMP8-IGF-I TG) in
which the aSMA promoter drives the expression of rat IGF-I
cDNA23 as a model to assess the role of HSC derived IGF-I on
Abbreviations: 28s, 28 ribosomal subunit; aSMA, smooth muscle a
actin; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
BrdU, bromodeoxyuridine; CCl4, carbon tetrachloride; cDNA,
complementary DNA; Cola1(I), procollagen a1(I); ECM, extracellular
matrix; HGF, hepatocyte growth factor; HSCs, hepatic stellate cells; IGF-
I, insulin-like growth factor I; IGFIR, IGF-I receptor 1; mRNA, messenger
RNA; RT-PCR, reverse transcription polymerase chain reaction; TG,
transgenic mice; TGFb1, transforming growth factor beta 1; UT,
untranslated region; WT, wild type mice.
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liver responses to acute CC14 induced injury in vivo. In this
mouse, the SMP8-IGF transgene is not detectable in normal
liver,23 presumably because aSMA positive cells are scarce.
We hypothesised that activation of HSCs by CCl4 would
induce expression of the SMP8-IGF-I transgene in the
activated HSCs and would allow us to define the effects of
HSC derived IGF-I on acute liver damage and repair in vivo.
METHODS
Animals
SMP8-IGF-I transgenic (TG) mice were derived as previously
described.23 The SMP8-IGF-I TG mice have germline integra-
tion of a transgene composed of the murine aSMA promoter
linked to a full length rat IGF-I cDNA. Hemizygous SMP8-
IGF-I TG males, on the FVB-N genetic background, were bred
with FVB-N WT females (Jackson Laboratories, West Grove,
PA, USA) to derive TG and WT mice for analyses. Study
protocols were in full compliance with NIH guidelines for
humane animal care.
CCl4 treatment
Ether sedated, 50–60 day old, sex matched TG and WT
littermates were given either a single dose of CCl4 (Sigma, St
Louis, MO, USA) or the same dose of corn oil by gavage
(3.5 ml/kg of body weight in a 1:1 mixture with corn oil).24 In
an initial study, mice were killed at 72 hours after CCl4, a
time when previous studies have established full activation of
HSCs in the mouse.25 In a follow up experiment, mice were
killed at 3, 8, 12, 24, 48, or 72 hours after CCl4 or vehicle
treatment. In this study, bromodeoxyuridine (BrdU; Sigma)
was given as a single intraperitoneal injection (120 mg/kg) at
90 minutes before sacrifice. Mice were anaesthetised with
Pentobarbital (Veterinary Laboratories Inc, Lanefa, KS, USA)
and killed by exsanguination.
IGF-I radioimmunoassay
Plasma IGF-I concentration was measured by radioimmuno-
assay after removal of IGF binding proteins by C18 cartridge
chromatography (Sep-Pak; Waters, Milford, MA, USA) as
previously described.26
Liver enzymes
Alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) levels were measured using standard clinical
automatic analyser (Hitachi 736).
RNA extraction and analyses
Liver RNA was extracted by a guanidine thiocyanate
homogenisation, cesium chloride sedimentation method as
detailed in Lund et al.27 20 mg of total RNA was analysed by
northern blot hybridisation using a 32P-labelled (Amersham,
Arlington Heights, IL, USA) antisense RNA probe comple-
mentary to rat IGF-I28 and a transgene specific RNA probe
complementary to the SV40 39 untranslated region present
within the SMP8-IGF-I transgene product.23 A mouse PL7
cRNA, encoding a ribosomal protein, was used as a control
for RNA loading.
Protein isolation and western blot
Frozen liver samples were homogenised in 10 mM Tris buffer
(pH 7.4) containing a cocktail of protease inhibitors (Sigma).
HSC were lysed in 10 mM Hepes buffer (pH 7.9) also
containing a protease inhibitor cocktail. Protein concen-
tration was determined using the Bio-Rad Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA). Extracts corre-
sponding to 50 mg of protein were separated on 12% non-
denaturing SDS polyacrylamide gels and transferred to PVDF
membranes (Immobilon-P; Millipore, Bedford, MA, USA), as
previously described.29 Filters were blocked in 10% non-fat
dry milk in TBS-T (20 mM Tris-HCl pH 7.6, 137 mM NaCl
and 1% Tween) before incubation with primary antibodies in
5% milk in TBS-T, for 60 minutes at room temperature. After
washing, membranes were incubated with HRP conjugated
secondary antibodies (Jackson Immuno Research
Laboratories, West Grove, PA, USA), and developed using
enhanced chemiluminescence light (ECL) detection kit
(Amersham Biosciences, Piscataway, NY, USA). Primary
antibodies used at 1:100 dilution were mouse mono-
clonal antibody to aSMA (Clone A4; Dako, Carpinteria, CA,
USA), and to BCL-XL (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and polyclonal antibodies to HGF (R&D
Systems, Minneapolis, MN, USA) and IGF-I (Santa Cruz
Biotechnology). A policlonal antibody against tubulin (Santa
Cruz Biotechnology) was used as a protein loading control.
Immunohistochemistry
Formalin fixed, paraffin embedded liver blocks were sec-
tioned at 6 mm and stained with haematoxylin and eosin to
evaluate morphology or with Masson’s trichrome and Sirius
red to detect collagen deposition. Immunohistochemistry to
localise aSMA and BrdU was performed as previously
described.29
Scoring of liver necrosis
Liver necrosis was graded on coded haematoxylin and eosin
stained sections by an experienced pathologist blinded to
treatment groups. Scoring was as follows: grade O, no visible
necrosis; grade I, focal necrosis of less than 25% of the liver
lobule area; grade II, confluent centrilobular necrosis of
25–50%; grade III, necrosis of 50–75%; grade IV, necrosis of
more than 75% of the liver lobule30
Isolation and culture of HSCs
HSCs from untreated TG and WT mice were isolated and
purified as described previously.25 HSCs were cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal
serum, 100 IU/ml penicillin, and 100 mg/ml streptomycin.
HSCs were plated out at a density of 106 cells/cm2. Quiescent
(newly isolated) and activated (day 14 in culture) HSCs were
studied. Total RNA from cultured HSCs was prepared using
TRI Reagent (Molecular Research Center, Cincinnati, OH,
USA) according to the manufacturer’s instructions.
RT-PCR
Expression of the transgene in cultured HSC was measured
using standard RT-PCR techniques. 1 mg of liver or HSC
derived total RNA was reverse transcribed to complementary
DNA (cDNA) using oligo(dT) and avian myeloblastosis virus
reverse transcriptase (Promega, Madison, WI, USA). The
sequence of a sense primer corresponding to aSMA 59 UT and
an antisense primer corresponding to SV40 39 UT of the
SMP8-IGF-I transgene, as well as specific primers used to
detect b-actin, are listed in table 1. Amplification reactions
were carried out as previously described31 using the GeneAmp
PCR System 2400 (Perkin-Elmer, Norwalk, CT, USA).
Real-time RT-PCR was also performed to quantify expres-
sion of the mRNAs of procollagen a1(I) (Cola 1(I)),
fibronectin, transforming growth factor beta 1 (TGFb1),
and the 28 ribosomal subunit (28s) using specific, intron
spanning, primers to avoid co-amplification of genomic DNA
(table 1). For real-time quantitative RT-PCR, reverse tran-
scription of total liver RNA to cDNA was done at 42 C˚ for
one hour using random primers (Boehringer Ingelheim,
Germany) and RTase (Gibco, Grand Island, NY, USA). During
PCR amplification, the cDNA was incubated with a mix
containing SYBR Green I, a dye specific for double stranded
DNA (LightCycler-FastStart DNA Master SYBR Green I;
Roche Diagnostics, Barcelona, Spain). Amplification
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conditions using a thermocycler (LightCycler; Roche
Molecular Biochemicals) were one step denaturation for
10 minutes at 95 C˚, followed by multiple cycles of denatura-
tion for 15 seconds at 95 C˚, annealing for five seconds at
61 C˚, and extension for 13 seconds at 72 C˚. The number of
cycles were: 26, 39, and 44 for 28s, Cola1(I), and TGFb1,
respectively. The specification of each PCR product was
established based on its melting temperatures (LightCycler
software version 3.39; Roche Molecular Biochemicals,
Indianapolis, IN, USA), and appropriate size was verified
on agarose gels. To prepare standards, PCR generated
fragments were isolated from agarose gels, purified
(GeneClean II; Q-Biogene, Carlsbad, CA, USA), cloned into
the pGEM T-Easy vector (Promega, Madison, WI, USA) and
sequenced (ABI PRISM 310 Genetic Analyzer; Perkin Elmer,
USA). Standard curves were generated from serial dilutions
of control linearised plasmids to obtain relative quantitation.
Results are presented as ratios of the relative concentrations
of Cola1(I) and TGFb1 to the 28s values.
Statistical analyses
Two way ANOVA was used to test for significance of effects
of the transgene (WT v TG) and CC14 treatment, and
interactions between transgene and treatment which indicate
an effect of transgene on reponses to CC14. Post hoc, pairwise
comparisons were performed using Duncan’s test. Mann-
Whitney U test for non-parametric inference was used when
appropriate, as indicated in the text.
RESULTS
Induction of SMP8-IGF-I mRNA
In the liver of TG mice the expression of SMP8-IGF-I
transgene, as assessed by RT-PCR, occurred as soon as eight
hours after CCl4 administration and tended to increase along
the 72 hours of the study period (fig 1A). Northern blot
analysis of liver samples obtained from WT and TG mice
72 hours after vehicle or CC14 administration showed that
the induction of the transgene occurred only in TG mice that
received CC14 (fig 1B). To confirm that the transgene is
specifically expressed in activated HSCs, we examined
transgene expression by RT-PCR in HSCs isolated from WT
and TG mice. HSCs were examined in quiescence and after
14 days of culture on plastic to induce activation.25 32 We
observed that SMP8-IGF-I mRNA was detected only in
activated TG HSCs (fig 1C).
Assays of plasma IGF-I revealed a significant (p,0.01)
decline in circulating IGF-I concentrations in both WT and
TG mice at 24 hours after CC14, but levels returned to normal
by 72 hours (table 2). At this time point, western blot for
IGF-I protein in the injured liver showed that the levels of
this growth factor was more intense in TG mice than in WT
animals (fig 1D), indicating that under conditions of liver
damage the hepatic production of IGF-I is higher in the
former group of animals.
Liver function and morphology
The livers of WT or TG mice receiving vehicle were
histologically unremarkable. At 24 and 48 hours after CCl4
administration the typical centrilobular hepatocellular necro-
sis induced by this compound could be seen in both groups of
animals (fig 2).33 34 However, at 72 hours the liver lesion was
largely resolved in TG mice while significant necrosis could
still be observed in WT animals (fig 2). Thus, at this time
point six out of eight WT mice showed severe hepatic necrosis
(grade III) and the other two had moderate necrosis (grade
II) while among TG mice six out of eight had virtually no
Table 1 Oligonucleotide sequences used in RT-PCR
reactions
mRNA Oligomers
SMP8-IGF-I Sense 59-GTG GCT TCT AGT GCT GAC G-39
Antisense 59-CCA CTC AGG CGT ATC AGT G-39
TGFb1 Sense 59-GAG TGG TTT GTT TGA GAT GT-39
Antisense 59-GGT TCG TGC ATC CAT TTC CA-39
Cola1(I) Sense 59-GCA AAG AGT AGT CTA CAT GTC TAG-39
Antisense 59-CCT ACA TCT TCT GAG TTT GG-39
Fibronectin Sense 59-TGT GAC AAC TGC CGT AGA CC-39
Antisense 59-GAC CAA CTG TCA CCA TTG AGG-39
b-actin Sense 59-GTG ACG AGG CCC AGA GCA AGA G-39
Antisense 59-AGG GGC CGG ACT CAT CGT-39
28s Sense 59-AGA AGG GCA AAA GCT CGC TT-39
Antisense 59-AGC AGG ATT ACC ATG GCA AC-39
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Figure 1 (A) Time course of liver expression of SMP8-IGF-I transgene
in TG mice after CCl4 treatment, measured by RT-PCR. (B)
Autoradiogram of a northern blot of liver RNA probed with a transgene
specific probe. Total RNA was extracted from the livers of six WT and six
TG mice at 72 hours after administration of vehicle or CCl4, as described
in Methods. 20 mg of total RNA from small intestine (a site of strong
transgene expression in smooth muscle cells) of TG mice was used as a
positive control (+C). (C) RT-PCR products obtained with oligomers
specific for the SMP8-IGF-I transgene and control b-actin. RT-PCR was
performed on RNA isolated from quiescent (Q) or activated (A) HSCs.
HSCs were activated by culture during 14 days on a plastic surface.
HSCs isolated from three WT and three TG mice were pooled for
extraction of RNA used for RT-PCR. +C, RT-PCR product from total RNA
from small intestine of SMP8-IGF-I TG mouse; 2C, negative control; M,
markers. (D) Representative western blot of IGF-I in liver tissue of WT
and TG mice at 0 h and 72 h after CCl4. Tubulin expression was used as
loading protein control.
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necrosis and other two exhibited necrosis of moderate degree
(grade II).
In agreement with these histological findings, serum
biochemistry demonstrated a dramatic increase in transami-
nase levels (.1000 IU/l) at 24 hours after CCl4 ingestion in
the two groups of animals, but recovery from hepatic damage
was more rapid in TG mice, which showed at 48 and 72 hours
values of serum transaminases significantly lower than those
found in WT littermates (table 3).
Liver regeneration
In order to label proliferating cells, BrdU was administered
90 minutes before sacrifice in animals examined at 24, 48,
and 72 hours after CCl4 treatment (fig 3). In both WT and TG
animals, BrdU positive cells were very rarely encountered at
24 hours after injury. At 48 hours we observed an intense
regeneration wave in TG mice which showed a frequency of
BrdU labelled hepatocytes significantly higher than the WT
littermates (218 (31) v 137 (7) positive nuclei per high power
field, p,0.05). At 72 hours, when the healing was almost
complete, the number of BrdU positive nuclei started
declining in TG mice (103 (23)), while it still was on the
rise in WT animals (182 (14)). These data indicate the
occurrence of an accelerated hepatocyte regeneration in TG
mice, which takes place with an anticipation of about
24 hours with respect WT littermates.
The transgenic IGF-I could stimulate liver regeneration
either directly or through other factors involved in the
regulation of hepatocyte proliferation. Mature HGF protein, a
complete mitogen for hepatocytes,18 can be detected in the
liver as early as six hours after CCl4
35 and reaches its maximal
values at 24 hours.4 14 Using western blot analysis of livers at
24 hours after CCl4 administration we found that the hepatic
Table 2 Plasma IGF-I concentration at 24 and 72 hours
after intragastric administration of CCl4
Vehicle 24 hours 72 hours
WT 417.7 (13.7) 226.6 (57.8)* 408.3 (90.1)
SMP8-IGF-I TG 422.3 (7.8) 227.0 (48.1)* 426.4 (51.2)
Data represent the mean (SEM) obtained from three mice in each group.
Two way ANOVA revealed significant effect of CCl4 treatment on the
concentrations of circulating IGF-I at 24 hours (p,0.01), but no effect of
genotype. *Significantly different from vehicle treated mice.
Figure 2 Liver morphology in WT and
SMP8-IGF-I TG mice treated with
vehicle and after CCl4 treatment. Livers
were harvested at 24, 48, or 72 hours
after intragastric administration of
vehicle or CCl4. Portions of the liver
were fixed, sectioned, and stained with
haematoxylin and eosin. Representative
photomicrographs from eight mice per
group are shown. Scale bar = 200 mm.
Table 3 Serum levels of AST and ALT in wild type and
SMP8-IGF-I mice after CCl4 administration
0 hours 24 hours 48 hours 72 hours
AST
WT 20 (2) 32580 (1957) 8087 (487) 2255 (366)
SMP8-IGF-I TG 21 (6) 24020 (4951) 2507 (158)* 1167 (479)*
ALT 0 hours 24 hours 48 hours 72 hours
WT 29 (8) 54600 (1693) 7623 (1051) 1880 (253)
SMP8-IGF-I TG 33 (7) 42100 (3864) 4780 (501)* 520 (178)
Values are expressed as IU/l and represent the mean (SEM) obtained from
three to six mice in each group. *p,0.05 compared with the respective group
of WT mice.
Figure 3 Immunohistochemical staining of the liver of WT and TG mice
following CCl4 treatment. Ninety minutes before sacrifice, at the times
indicated in the figure, mice received intraperitoneal injection of BrdU to
visualise proliferating cells. Livers were harvested, processed, and
stained for BrdU as described in Methods. Representative
photomicrographs are shown; arrows show positive nuclei. Scale
bar = 200 mm.
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levels of HGF were higher in TG mice than in WT animals
(fig 4A and B). The levels of HGF in hepatic tissue still
remained higher in TG than in WT mice at 72 hours after the
toxic challenge (data not shown). In order to determine
whether the increased production of HGF might be derived
from enhanced production of this factor by activated
transgenic HSC, we analysed by western blot the production
of HGF in extracts of transgenic and wild type HSC in a
quiescent status or after activation by culturing during
14 days. As shown in figure 4C, we found that HGF was
produced only by activated TG HSC, but not by WT HSC, nor
by quiescent HSC. These data show that transgenic IGF-I may
act autocrine/paracrine fashion to activate HGF production in
HSC.
High levels of TGFb1 inhibit liver regeneration20 whereas
low levels have been shown to have a permissive effect on
hepatocyte replication.36 37 In our study we found that
compared with WT, TG animals tended to express lower
levels of TGFb1 mRNA during the whole study period,
the differences being statistically significant (p,0.05,
Mann-Whitney U-test) at 24 hour after CCl4 administration
(fig 5A). At this time point TGFb1 mRNA expression was
increased (relative to animals that received vehicle) 5.84
(0.72) fold in WT and only 2.04 (0.47) fold in TG. TGFb1
mRNA expression was also analysed in HSC from TG and WT
mice activated by culture on plastic for 14 days. We found
that HSC obtained from TG mice showed a three fold
reduction in TGFb1 mRNA expression compared with those
obtained from WT mice (fig 5B). Again these observations
indicate that the transgenic IGF-I can repress the synthesis of
the profibrogenic cytokine TGFb1 by HSC either directly or
indirectly through stimulation of HGF production.
Collagen and fibronectin expression
Acute CCl4 induced liver injury is accompanied by transient
elevation in the expression of Cola1(I) mRNA.25 38 In our
study Cola1(I) mRNA levels were significantly (p,0.05)
increased in both WT and TG mice at 48 and 72 h after CCl4
treatment (fig 5C, left). At 72 hours, the increase in Cola1(I)
mRNA values (relative to mice receiving vehicle) was
significantly lower (p,0.05) in CCl4 treated TG mice than
in CCl4 treated WT littermates (fig 5C, left). Despite up-
regulation of Cola1(I) mRNA, no collagen accumulation in
the liver in either genotype was visualised using Masson’s
trichrome or Sirius red stains in our model of acute CCl4 liver
injury.
The expression of fibronectin, another ECM component,
remained largely unchanged except at 72 hours, when its
mRNA levels (relative to mice given vehicle) were signifi-
cantly lower (p,0.05) in CCl4 treated TG animals than in WT
mice that received the hepatotoxin (fig 5C, right).
Activation of HSC
aSMA staining was negligible in the liver of WT or TG mice
that received vehicle. By contrast a dramatic increase in the
number of aSMA positive cells was present in the livers of WT
mice given CCl4. Interestingly, fewer aSMA positive cells
were detected in TG mice at 72 hours after CCl4 ingestion and
were located around the central vein (fig 6, top). To confirm
the immunohistochemical findings, aSMA expression in the
liver extracts was analysed by immunoblot. As illustrated in
figure 6 (bottom), aSMA was not detectable in vehicle
treated WT or TG mice whereas it was strongly induced after
CCl4 administration in WT (seven out of seven) but in only
one out of six TG mice examined.
Apoptosis of activated HSCs has been reported in some
models during resolution of liver injury.39 40 We performed
TUNEL assays to determine if increased apoptosis accounted
for the lower numbers of activated HSC in TG mice. No
TUNEL positive HSCs were found in livers of vehicle or CCl4
treated WT or TG mice (data not shown) indicating that
apoptosis of HSC is minimal in the mouse CC14 model of
acute liver injury. Furthermore, we evaluated by western blot
the expression of the antiapoptotic protein BCL-XL, whose
levels are usually decreased in liver damage.41 We found that
the reduction induced by CCl4 at 72 hours after toxic
ingestion in both genotypes was less intense in TG than in
WT mice (fig 7).
DISCUSSION
In the present study transgene expression was not detectable
in the normal liver of SMP8-IGF-I TG mice, despite the fact
that aSMA is present in the scant smooth muscle cells of the
intrahepatic branches of the hepatic artery. A low level of
transgenic expression in these structures which represent a
minimal part of the hepatic mass might determine that the
abundance of SMP8-IGF-I mRNA in normal transgenic liver
is below the detection threshold of the PCR technique used in
our study. By contrast we show that in SMP8-IGF-I TG mice
the transgene is induced in the liver after CCl4 injury and in
isolated HSCs upon activation, thus demonstrating that the
        
	
	 		
 	


 
 
     !"#
$" %%
&! 
'

	(
'

	(
')  
* + * +
	 ,

+
-
%
Figure 4 (A) Western blot analysis of HGF levels in the livers of CCl4
treated WT and SMP8-IGF-I TG mice. Proteins were extracted, as
described in Methods, from livers harvested at 24 hours following
intragastric administration of vehicle or CCl4. Western blot was
performed using anti-HGF polyclonal antibody, and tubulin was used as
protein loading control. (B) The intensity of each band was quantified
using an image analyser. Results are expressed as the ratio between the
density signal in CCl4 treated mice to the density signal in vehicle treated
mice set arbitrarily at 1.0. Data represent the mean (SEM) obtained from
three mice per group. a: significantly different (p,0.05) from WT mice
(Mann-Whitney U test). (C) Representative photomicrograph of western
blot analyses of HGF levels in HSC obtained from WT and SMP8-IGF-I
transgenic mice, and activated by culturing during 14 days; tubulin was
used as protein loading control. Q: Quiescent HSC; A: Activated HSC.
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aSMA promoter is a useful tool to deliver expression of
selected genes specifically to activated HSCs. This model
allowed us to analyse the effect of HSC derived IGF-I on the
liver response to injury.
Massive necrosis of hepatocytes after CCl4 ingestion is
followed by a replicative response which is orchestrated by a
highly complex cytokine cascade. The whole reparative
process is usually completed within five days.42 Our results
show that injury induced expression of the SMP8-IGF-I gene
in activated HSCs in vivo was not sufficient to clearly
diminish initial damage by CCl4, but did lead to accelerated
liver regeneration, improved liver morphology and biochem-
istry, and fewer activated HSCs by 72 hours after CCl4,
indicating an effect of the transgene in the improvement of
the recovery after injury. This rapid cure seems to result from
stimulation of liver cell regeneration, but we cannot
completely exclude the contribution of a direct or indirect
effect of IGF-I on the modulation of the intensity of
hepatocellular damage.
We have observed that IGF-I protein can be detected by
western blot at higher levels in the liver of TG mice than in
WT mice. As the concentration of circulating IGF-I is similar
in WT and TG mice after injury, it seems that improved
healing observed in TG mice may result from the autocrine/
paracrine effects of transgene derived IGF-I induced in HSCs
upon activation.
SMP8 IGF-I-derived IGF-I could act indirectly by modulat-
ing the synthesis of other growth factors which regulate
hepatocellular proliferation. We focused our attention on
HGF, a complete mitogen for hepatocytes that increases
transiently in the injured liver,18 43 and TGFb1, a known
inhibitor of hepatocyte growth which is induced after CCl4
injury.20 In our study we observed, at 24 hours after injury, a
more intense increase of HGF in the liver of TG mice than in
WT animals. The increase in HGF expression persisted,
although at lower levels at 72 hours. This finding suggests
that the HSC derived IGF-I may accelerate healing at least in
part by enhancing the HGF response to injury. This
interpretation is supported by earlier findings demonstrating
induction of HGF by IGF-I in HSCs in vitro16 17 and by our
data showing that HSC from TG mice produce more HGF
upon activation than wild type HSC.
TGFb1 is a multifunctional cytokine which on one hand
activates HSCs and promotes fibrogenesis1 and on the other
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Figure 5 (A) Real-time RT-PCR analyses of TGFb1 mRNA values in the livers of WT and SMP8-IGF-I TG mice. Livers were harvested at indicated times
following treatment with vehicle or CCl4. Total RNA was extracted and processed as detailed in Methods. Following amplification, mRNA levels were
standardised to those of the housekeeping gene 28s. Results are expressed as the ratio between relative values of TGFb1 mRNA in CCl4 treated mice to
those of TGFb1 mRNA in vehicle treated mice set arbitrarily at 1.0. Data represent the mean (SEM) from three to six mice per group analysed at each
time point. b: significantly different (p,0.01) from vehicle treated group; c: significantly different (p,0.05) from TG mice. (B) Real time RT-PCR
analyses of TGFb1 mRNA levels in HSC obtained from WT and transgenic mice, activated during 14 days in culture. Total RNA was extracted and
processed as detailed in Methods. Units were calculated from the formula: 2DCt610000 (DCt = number of cycles of housekeeping gene minus number
of cycles of TGFb1). Data represent the mean (SEM) from 10–12 experiments. Statistical significances are shown in the figure. (C) Real-time
quantitative RT-PCR analyses of expression of procollagen a1(I) (left panel) and fibronectin (right panel) in the livers of WT and SMP8-IGF-I TG mice
harvested at indicated time points following vehicle or CCl4 treatment (see methodological details in (A)). Data represent the mean (SEM) from three to
six mice per group analysed at each time point. a: significantly different (p,0.05) from vehicle-treated group; b: significantly different (p,0.05) from
TG mice (Mann-Whitney U test).
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hand inhibits hepatocyte proliferation.20 The observed
decrease in TGFb1 in TG mice (fig 5) could contribute to
accelerated liver regeneration36 37 as well as to the reduction
in the number of aSMA positive HSCs.21 25 This reduction
does not appear to be due to increased apoptosis of HSC
because no apoptotic HSC were detected either in WT or TG
mice, and BCL-XL was more intensely expressed in TG than in
WT livers (fig 7). The process of activation of HSCs involves a
TGFb1 independent initiation phase followed by TGFb1
dependent perpetuation phase.25 The reduced number of
aSMA positive HSCs found in TG mice could reflect
attenuated perpetuation, consistent with the low TGFb1
mRNA levels observed both in liver tissue and HSC in these
animals. The exact mechanism of inhibition of TGFb1 mRNA
expression by IGF-I remains unknown, but could involve the
ability of IGF-I to increase antioxidant activity of catalase in
the liver44 or lower numbers of activated HSCs expressing
TGFb.
Our results show that IGF-I induction in HSCs attenuates
collagen expression during acute liver injury in TG mice. It
seems likely that the decrease in collagen mRNA may result
from different factors including reduced injury, enhanced
production of HGF (a hepatotrophic factor known to suppress
hepatic fibrogenesis19) and decreased TGFb1 mRNA. In spite
of increased collagen gene expression, neither WT nor TG
mice showed signs of accumulation of collagen in this model
of acute liver injury (data not shown) which is consistent
with reports in other strains.24
Although we were able to detect IGF-I by western blot in
livers from TG mice after toxic challenge, we could not
definitively localise SMP8-IGF-I transgene expression solely
to HSCs. Attempts to localise transgene by in situ hybridisa-
tion or histochemistry proved problematic because of high
non-specific binding of cRNA probes or IGF-I antibodies to
necrotic tissue and because the transgene specific probe is
small and has limited sensitivity. We cannot exclude that the
transgene expression is induced in other cell types as well as
in HSCs, such as vascular smooth muscle cells. In any case,
the dramatic improvement in repair in SMP8-IGF-I TG,
despite similar circulating IGF-I as in WT, indicates that the
effect reflects local transgene induction in HSCs and possibly
other cell types with resulting largely paracrine activities. It is
also important to note that the beneficial effect of HSC
derived IGF-I during acute injury does not anticipate what
would be the role of HSC derived IGF-I in fibrosis associated
with chronic injury. We have attempted to compare the
responses of SMP8-IGF-I TG and WT to chronic CCl4 induced
injury and fibrosis but this FVB strain appears resistant to
fibrosis (unpublished data).
In conclusion, our study demonstrates that the SMP8
promoter is a useful tool to deliver genes of interest to
activated HSCs in vitro and to injured liver and, likely, to
activated HSCs in vivo. SMP8-IGF-I induction in the liver in
vivo during CCl4 injury accelerates liver regeneration and this
is associated with increased production of HGF, reduced
expression of TGFb1, and reduced collagen mRNA expres-
sion. Together these data support a beneficial role of HSC
derived IGF-I in tissue repair after acute liver injury.
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Figure 6 Top: Immunohistochemical staining of the liver with antibody
specific for aSMA. Sections of the livers from WT and SMP8-IGF-I TG
mice, harvested at 72 hours following vehicle or CCl4 treatment, were
stained with anti-aSMA monoclonal antibody as described in Methods.
Representative photomicrographs from eight mice per group are shown.
Scale bar = 200 mm. Bottom: Representative western blot of analyses of
aSMA (46 kDa) levels in the livers obtained from the same experiment.
Tubulin western blot is included as a loading protein control.
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Figure 7 Representative western blot of BCL-XL levels in the livers
obtained from WT and SMP8-IGF-I TG mice, harvested at 72 hours
following vehicle or CCl4 treatment. Tubulin western blot is included as a
loading protein control.
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